BioLife Solutions (NASDAQ:BLFS) Upgraded at StockNews.com

StockNews.com upgraded shares of BioLife Solutions (NASDAQ:BLFS) from a sell rating to a hold rating in a research report released on Tuesday morning.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a report on Tuesday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, BioLife Solutions presently has an average rating of “Moderate Buy” and a consensus target price of $31.17.

BioLife Solutions Trading Down 0.3%

Shares of BLFS stock opened at $21.99 on Tuesday. BioLife Solutions has a fifty-two week low of $18.70 and a fifty-two week high of $29.55. The stock’s fifty day moving average price is $23.58 and its two-hundred day moving average price is $25.29. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company has a market cap of $1.04 billion, a PE ratio of -20.75 and a beta of 2.01.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million. Equities analysts predict that BioLife Solutions will post -0.3 EPS for the current fiscal year.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 8,902 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $201,719.32. Following the completion of the transaction, the chief marketing officer now directly owns 135,956 shares in the company, valued at approximately $3,080,762.96. This represents a 6.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sarah Aebersold sold 2,695 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $25.44, for a total transaction of $68,560.80. Following the transaction, the insider now directly owns 43,165 shares of the company’s stock, valued at $1,098,117.60. The trade was a 5.88% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,696 shares of company stock worth $1,665,094. 2.20% of the stock is currently owned by insiders.

Institutional Trading of BioLife Solutions

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. acquired a new stake in shares of BioLife Solutions in the first quarter valued at about $30,789,000. Raymond James Financial Inc. acquired a new stake in BioLife Solutions during the 4th quarter valued at approximately $20,664,000. Massachusetts Financial Services Co. MA bought a new position in BioLife Solutions during the 4th quarter worth approximately $19,805,000. Royal Bank of Canada raised its holdings in BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after purchasing an additional 617,320 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of BioLife Solutions in the 4th quarter worth approximately $11,113,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.